Schedule 13G ownership disclosure
Innate Pharma SA
Ordinary Shares, nominal value (euro) 0.05 per share (including ordinary shares represented by American Depositary Shares) · CUSIP: 45781K105
Event date: 2025-12-31
- Filing-level shares
- 7,333,778.00
- Percent of class
- 7.82%
- Novo Nordisk A/S
Shares: 7,333,778.00 · Class: 7.82%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000950103-26-003227
- Form type
- SCHEDULE 13G/A
- Filer
- Innate Pharma SA
- CIK
- CIK 1598599
- Filed
- Mar 04, 2026
- Reporting period
- Dec 31, 2025
- Description
- Schedule 13G beneficial ownership